Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v1-EN
Language French English
Date Updated 2020-01-16 2019-02-21
Drug Identification Number 02401029 02401029
Brand name CEFAZOLIN FOR INJECTION, USP CEFAZOLIN FOR INJECTION, USP
Common or Proper name Cefazolin for Injection, USP Cefazolin for Injection, USP
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients CEFAZOLIN CEFAZOLIN
Strength(s) 100G 100G
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 100g SmartPak 100g SmartPak
ATC code J01DB J01DB
ATC description OTHER BETA-LACTAM ANTIBACTERIALS OTHER BETA-LACTAM ANTIBACTERIALS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2019-11-01 2019-02-21
Actual start date
Estimated end date 2019-12-16 Unknown
Actual end date 2020-01-13
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Product Available 25% Allocation effective January 13th, 2020 Fresenius Kabi Canada Ltd. regrets to advise that due to a production interruption, we will be placing our Cefazolin for Injection, USP 100 g SmartPak® on reduced allocation. Contract customers will be allocated 50% of their historical average monthly volumes. If you have any questions or concerns, please do not hesitate to contact Customer Service at (877) 821-7724.
Health Canada comments